PT964697E - Aplicacoes terapeuticas de antigenios ou epitopos, associados com um processamento celular de peptidos deficiente, e.g. expressos em celulas rma-s transfectadas com um gene b7-1 - Google Patents

Aplicacoes terapeuticas de antigenios ou epitopos, associados com um processamento celular de peptidos deficiente, e.g. expressos em celulas rma-s transfectadas com um gene b7-1

Info

Publication number: PT964697E
Authority: PT; Portugal
Prior art keywords: antigens; epithopes; peptid; rma; gene
Prior art date: 1996-12-12

Application number

PT97948102T

Other languages

English (en)

Inventor

Elisabeth Wolpert

Klas Karre

Max Pettersson

Johan Sandberg

Original Assignee

Accuro Immunology Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-12

Filing date

1997-12-12

Publication date

2003-07-31

1997-12-12 Application filed by Accuro Immunology Ab filed Critical Accuro Immunology Ab

2003-07-31 Publication of PT964697E publication Critical patent/PT964697E/pt

Links

239000000427 antigen Substances 0.000 title abstract 3
108091007433 antigens Proteins 0.000 title abstract 3
102000036639 antigens Human genes 0.000 title abstract 3
108090000623 proteins and genes Proteins 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1
230000001771 impaired effect Effects 0.000 abstract 2
102000043129 MHC class I family Human genes 0.000 abstract 1
108091054437 MHC class I family Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
241000700605 Viruses Species 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000001413 cellular effect Effects 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
230000003053 immunization Effects 0.000 abstract 1
238000002649 immunization Methods 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

PT97948102T 1996-12-12 1997-12-12 Aplicacoes terapeuticas de antigenios ou epitopos, associados com um processamento celular de peptidos deficiente, e.g. expressos em celulas rma-s transfectadas com um gene b7-1 PT964697E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9604581A SE9604581D0 (sv)	1996-12-12	1996-12-12	An agent against cancer and virus infections

Publications (1)

Publication Number	Publication Date
PT964697E true PT964697E (pt)	2003-07-31

Family

ID=20404956

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT97948102T PT964697E (pt)	1996-12-12	1997-12-12	Aplicacoes terapeuticas de antigenios ou epitopos, associados com um processamento celular de peptidos deficiente, e.g. expressos em celulas rma-s transfectadas com um gene b7-1

Country Status (12)

Country	Link
US (1)	US20030087846A1 (pt)
EP (1)	EP0964697B1 (pt)
JP (1)	JP2001517208A (pt)
AT (1)	ATE234628T1 (pt)
AU (1)	AU5423898A (pt)
CA (1)	CA2274837A1 (pt)
DE (1)	DE69720065T2 (pt)
DK (1)	DK0964697T3 (pt)
ES (1)	ES2193408T3 (pt)
PT (1)	PT964697E (pt)
SE (1)	SE9604581D0 (pt)
WO (1)	WO1998025645A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2005524601A (ja) *	2000-09-15	2005-08-18	ザスクリップスリサーチインスティテュート	抗体による過酸化水素およびスーパーオキシド生成に関する方法および組成物
EP1994406A1 (en) *	2006-03-16	2008-11-26	Leiden University Medical Center	Methods for identifying t-cell epitopes associated with impaired peptide processing and applications of the identified epitopes
EP2089513A1 (en) *	2006-12-07	2009-08-19	Publiekrechtelijke rechtspersoon Academisch Ziekenhuis Leiden h.o.d.n. Leids Universitair Medisch Centrum	Use of a varicellovirus tap-inhibitor for the induction of tumor- or virus-specific immunity against teipp
US10155038B2 (en)	2007-02-02	2018-12-18	Yale University	Cells prepared by transient transfection and methods of use thereof
WO2008097926A2 (en) *	2007-02-02	2008-08-14	Yale University	Transient transfection with rna
US9249423B2 (en)	2007-02-02	2016-02-02	Yale University	Method of de-differentiating and re-differentiating somatic cells using RNA
WO2009008713A1 (en) *	2007-07-09	2009-01-15	Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Ce	Tap-inhibitors from old world primate 1-herpesviruses and their use
FR2931485B1 (fr) *	2008-05-23	2011-06-17	Centre Nat Rech Scient	Vaccin antitumoral comprenant des cellules tumorales modifiees
WO2012089225A1 (en) *	2010-12-29	2012-07-05	Curevac Gmbh	Combination of vaccination and inhibition of mhc class i restricted antigen presentation
MA39818A (fr)	2014-03-30	2017-02-08	Benevir Biopharm Inc	Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
CN115023268A (zh) *	2020-01-29	2022-09-06	迈阿密大学	针对被病原体感染的细胞中诱导的抗原的疫苗接种
CN111979243B (zh) *	2020-08-24	2023-05-23	大连大学	利用CRISPR/Cas9系统构建TAP基因缺失的猪T2细胞的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2024458A1 (en) *	1970-05-20	1971-12-02	Hartmann geb. Ungewitter, Philippine, Dr., 8000 München	Tumour antigen - modified and potentiated by irradiation
DE2918927A1 (de) *	1979-05-10	1980-11-20	Hans Prof Dr Limburg	Arzneipraeparat zur behandlung von carcinomen und verfahren zu dessen herstellung
ES2139012T3 (es) *	1992-05-26	2000-02-01	Univ Leiden	Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
CA2107537C (en) *	1992-10-02	2007-01-30	Lieping Chen	Inhibition of tumor cell growth by administration of b7-transfected cells
US5750398A (en) *	1993-11-30	1998-05-12	David C. Johnson	Vector, element and method for inhibiting immune recognition
WO1996009380A1 (en) *	1994-09-23	1996-03-28	The University Of British Columbia	Method of enhancing expression of mhc class i molecules bearing endogenous peptides
CA2230195A1 (en) *	1995-08-21	1997-02-27	Duke University	A method to increase the density of antigen on antigen presenting cells

1996
- 1996-12-12 SE SE9604581A patent/SE9604581D0/xx unknown
1997
- 1997-12-12 DE DE69720065T patent/DE69720065T2/de not_active Expired - Fee Related
- 1997-12-12 WO PCT/SE1997/002094 patent/WO1998025645A1/en not_active Ceased
- 1997-12-12 JP JP52656398A patent/JP2001517208A/ja not_active Ceased
- 1997-12-12 CA CA002274837A patent/CA2274837A1/en not_active Abandoned
- 1997-12-12 AU AU54238/98A patent/AU5423898A/en not_active Abandoned
- 1997-12-12 AT AT97948102T patent/ATE234628T1/de not_active IP Right Cessation
- 1997-12-12 ES ES97948102T patent/ES2193408T3/es not_active Expired - Lifetime
- 1997-12-12 US US09/319,736 patent/US20030087846A1/en not_active Abandoned
- 1997-12-12 EP EP97948102A patent/EP0964697B1/en not_active Expired - Lifetime
- 1997-12-12 PT PT97948102T patent/PT964697E/pt unknown
- 1997-12-12 DK DK97948102T patent/DK0964697T3/da active

Also Published As

Publication number	Publication date
DE69720065T2 (de)	2003-12-04
ES2193408T3 (es)	2003-11-01
ATE234628T1 (de)	2003-04-15
WO1998025645A1 (en)	1998-06-18
EP0964697B1 (en)	2003-03-19
AU5423898A (en)	1998-07-03
JP2001517208A (ja)	2001-10-02
US20030087846A1 (en)	2003-05-08
SE9604581D0 (sv)	1996-12-12
DK0964697T3 (da)	2003-04-22
DE69720065D1 (de)	2003-04-24
CA2274837A1 (en)	1998-06-18
EP0964697A1 (en)	1999-12-22

Publication	Publication Date	Title
PT851927E (pt)	2004-03-31	Compostos para imunoterapia e diagnostico de tuberculose
HUP9901186A2 (hu)	1999-07-28	Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra
NO20075902L (no)	2000-01-18	Forbindelser for immunoterapi og diagnose av turberkolose og metoder for deres anvendelse
ATE418562T1 (de)	2009-01-15	Ctl epitope des epstein-barr virus
PT964697E (pt)	2003-07-31	Aplicacoes terapeuticas de antigenios ou epitopos, associados com um processamento celular de peptidos deficiente, e.g. expressos em celulas rma-s transfectadas com um gene b7-1
WO1996011279A3 (en)	1996-05-17	Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
AR014182A1 (es)	2001-02-07	Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones
WO1999042076A3 (en)	1999-10-14	Compounds and methods for immunotherapy and diagnosis of tuberculosis
ES2194836T3 (es)	2003-12-01	Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana.
ATE179614T1 (de)	1999-05-15	Herpes simplex virus vp16 impfstoffe
TR200102034T2 (tr)	2001-11-21	Anti kanser aşılaması için antikorların kullanılması
BR0010711A (pt)	2002-02-13	Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
MY141459A (en)	2010-04-30	Recombinant anti-idiotypic antibodies
AU2003241127A1 (en)	2003-12-31	MEMBRANE-ANCHORED Beta2 MICROGLOBULIN COVALENTLY LINKED TO MHC CLASS I PEPTIDE EPITOPES
DE69738512D1 (de)	2008-03-27	Epstein-barr virus type b ctl epitopen
BR0009077A (pt)	2002-04-16	Antìgenos de tuberculose e métodos de uso dos mesmos
ES2105984A1 (es)	1997-10-16	Adenovirus recombinantes que expresan antigenos del virus de la gastroenteritis porcina transmisible (vgpt) y su empleo en la formacion de vacunas.
SE9600436D0 (sv)	1996-02-06	Vaccine against hantavirus
BR0016740A (pt)	2002-09-03	Antìgenos de esporozoìto de cryptosporidium
UA81613C2 (ru)	2008-01-25	Стимуляция тимозином генетической иммунизации
AR010517A1 (es)	2000-06-28	Compuestos y metodos para la inmunoterapia y diagnostico de tuberculosis
CY1108543T1 (el)	2014-04-09	Εμβολια dna που κωδικοποιουν βοηθητικες πρωτεϊνες του hiv